Furthermore, several case reports showed that skin symptoms suspected to be DLE or CLE developed after application of infliximab, adalimumab and bevacizumab (TNF-α inhibitors), indicating that TNF-α inhibitors may not be appropriate for the treatment of DLE (54–56). Here, TNF is linked to discoid lupus erythematosus.